Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. Pang LL, Gan JD, Huang YH, Liao J, et al. BMC Cancer 2023;23:72.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pang LL, Gan JD, Huang YH, Liao J, et al. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. BMC Cancer 2023;23:72.
PMID: 36670414